• 6 min read
• Published on 21 October 2025
Listen to article
7:08Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
The King is Dead: A New Guard in Autoimmune Drugs
For what felt like an eternity in the fast-moving world of pharmaceuticals, Humira was the undisputed king. It was the go-to drug for a host of grim autoimmune conditions, a titan that raked in over $20 billion a year for its maker, AbbVie. To me, it always felt like the reliable old Land Rover of treatments, dependable, but perhaps not the most cutting-edge piece of kit anymore. Well, the time has come to trade it in. The king, it seems, has been dethroned not by a cheap imitation, but by its own, far cleverer, heir apparent.
In a series of head-to-head clinical trials, AbbVie’s next-generation drug, Rinvoq, didn’t just edge out its older stablemate, it gave it a proper thrashing. The data showed Rinvoq achieving significantly better results in treating rheumatoid arthritis, pushing more patients into remission. This wasn't just a minor tweak or a statistical anomaly. The full breakdown of the Rinvoq vs Humira Results | Immunology Market Shift signals a fundamental power shift in a multi-billion-pound market. It proves that genuine innovation can, and will, eclipse even the most entrenched blockbuster drugs.
So, a new drug is better than an old one. Hardly stop-the-press news, is it? But for an investor, this is where it gets interesting. Humira is facing its 'patent cliff', that terrifying moment when its market protection expires and cheaper biosimilar versions flood in. Many companies would simply try to cling on, squeezing the last drops of revenue from their fading star. AbbVie, however, played a blinder. They spent years and a fortune developing their own successor, effectively disrupting themselves before anyone else could. It’s a masterclass in long-term strategy.
This isn't just an AbbVie story, though. It’s a blueprint for the entire sector. The crumbling of old patent walls creates a vacuum, and smart money is watching to see who fills it. We see companies like Vertex Pharmaceuticals, known for its work in rare diseases, now wading into immunology with fresh ideas. Then you have smaller, nimbler outfits like Aurinia Pharmaceuticals, carving out lucrative niches by targeting specific conditions like lupus nephritis. The game is no longer just about defending old territory, it’s about conquering new ground with superior technology.
What makes these new drugs so much better? In simple terms, they’re more precise. Old guards like Humira are a bit like using a blanket to put out a candle, they dampen a broad part of the immune system. Rinvoq, a so-called JAK inhibitor, is more like a sniper. It targets a more specific pathway involved in inflammation. The real kicker for patients, and a huge commercial advantage, is that it’s a pill. No more fiddling with injectable pens. When you combine superior effectiveness with greater convenience, you have a recipe for commercial success.
The investment case here seems quite straightforward. You have a vast and growing market of patients, many of whom are poorly served by existing treatments. Now, a new class of therapy has proven it can deliver better outcomes. Companies that can successfully bring these drugs to market could be poised to capture enormous value. Regulators, for their part, are often keen to fast-track genuinely innovative treatments that address a clear medical need, which might help de-risk the development timeline somewhat.
Of course, this is the pharmaceutical sector, and it’s never a one-way bet. For every Rinvoq, there are dozens of promising molecules that fail spectacularly in late-stage trials, incinerating billions in research capital. Competition is brutal, and even a superior drug has to fight for market access and favourable pricing from health services. Investing here requires a strong stomach and an appreciation for the science, but for those who get it right, the rewards could be substantial. The old guard is fading, and the race to crown the next king is well and truly on.
View the full Basket:Rinvoq vs Humira Results | Immunology Market Shift
View the full Basket:Rinvoq vs Humira Results | Immunology Market Shift
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article